Trial Profile
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; IRX 2 (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- 11 Nov 2022 Status changed from active, no longer recruiting to completed.
- 23 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2021 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.